Biogen Financial News

Subscribe to enjoy similar stories. A group of technology companies is investing in a new form of carbon capture that aims to cut emissions from household waste in an effort to reduce landfill usage and to lower the amount of greenhouse gas emissions that are emitted into the atmosphere. Frontier, an umbrella group of tech companies including payments firm Stripe, internet giant Google and Instagram parent Meta is investing just under $32 million in a carbon-capture-and-storage project in Norway in the hope of removing 100,000 metric tons of carbon from the atmosphere between 2029 and 2030.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

Shares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval

Federal regulators are putting off a decision on Eli Lilly’s potential Alzheimer’s treatment with an unusual request to have an advisory committee examine the drug

portfolio companies as a routine, but amidst the flurry of analysis, have you ever paused to reflect on how much of their inner working we truly grasp? How many acclaimed attributes of greatness remain valid, and how much can we discern from a distance? These questions hold significant implications for the valuations we are prepared to endorse, moulding our long-term returns. Permit me to recount the story of Amgen, a leading biotechnology company based in the United States, as an illustrative case study. A notable book that emphasized the importance of corporate culture by looking at successful companies (stock price performance as a guide) ranked Amgen prominently. Amgen's adeptness in «embracing a myriad of possible dangers» was a strategic manoeuvre that propelled the company to a superior standing.

Investing.com — Here is your Pro Recap of the earnings reports you may have missed this week: Coinbase, Airbnb, Coca-Cola, Cisco Systems, and Biogen.

(Updated — February 13, 2024 11:19 AM EST)

Biogen (NASDAQ:BIIB) shares are down more than 5% premarket Tuesday after the company reported earnings for its latest quarter, missing the consensus profit and revenue estimate.

Mint, Kolli had said that AM Green is in talks with various international and domestic lenders for firming up debt. He added that upon achieving 5 million tonnes per annum (MTPA) green ammonia production scale, AM Green will clock $4 billion in top line and $1.6 billion in run rate Ebitda basis.

Keppel Corporation’s infrastructure division and AM Green, which is wholly owned by the founders of Hyderabad-based Greenko, have decided to jointly explore opportunities in producing biogenic carbon-based sustainable fuels in South-east Asia and the Middle East. These sustainable fuels can serve as an environmentally sustainable alternative to fossil fuels to support the decarbonisation of heavy industrial operations and the aviation sector. The companies estimate that these two regions can harness and aggregate at least a million tonnes of biogenic carbon dioxide per year.

NEW DELHI : Hyderabad-based pharmaceutical company Dr Reddy’s Laboratories Ltd (DRL), will invest ab out ₹700 crore for capacity expansion during the second half of the fiscal, G. V. Prasad, co-chairman and managing director of DRL told Mint.

By Chuck Mikolajczak

Stocks surged aggressively last week as investor bets rose that rates have peaked in the aftermath of the FOMC’s decision to leave rates unchanged. Moreover, the labor market data cooled, signaling the Fed is done hiking.

By Deena Beasley

Advent International on Friday announced the completion of its majority acquisition of Hyderabad-based listed contract development and manufacturing organisation (CDMO) Suven Pharma. Advent acquired 50.1% stake in Suven at an agreed price of Rs 495/share in December last year a firm promoted Venkat Jasti and his family members for Rs 6,313 crore paying ₹495 per share.

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies

Dr Reddy's Laboratories (DRL) has joined the race to acquire the biosimilar products portfolio of US-based Biogen in a transaction worth a potential $1 billion, according to two people aware of the development. Another Indian company in the fray is Intas Pharmaceuticals, Mint reported on September 13. According to reports, Samsung Bioepis is also a candidate to acquire the portfolio. Biogen joined hands with Samsung biosimilars production unit Samsung Biologics to establish Samsung Bioepis in 2012 for developing biosimilars. As part of exiting its biosimilars business, Biogen sold off its stake in Samsung Bioepis at $2.3 billion in February last year.

MUMBAI : Intas Pharmaceuticals Ltd is preparing a bid for Biogen Inc.’s biosimilar business in a transaction that could be valued at as much as $1 billion, two people familiar with the talks said. Ahmedabad-based Intas is being advised by Goldman Sachs Group Inc., one of the people said, adding that the company has submitted a non-binding bid and is seeking to put a binding one later this month. “This is still at an early stage," the second person said on condition of anonymity.

blood test that detected Parkinson's disease in a preliminary study could become the first specific tool for diagnosing the devastating neurodegenerative condition, researchers said on Wednesday. The test, which looks for cell damage associated with the disease, is years away from being commercially available. If its reliability is confirmed in future trials, the test would allow doctors to diagnose the condition earlier and start therapies sooner, before nervous system damage worsens, the researchers said. «Currently, Parkinson's disease is diagnosed largely based on symptoms, when patients already have significant neurological damage,» said study leader Laurie Sanders of Duke School of Medicine in Durham, North Carolina. The new blood test measures DNA damage in mitochondria, the structures inside cells that generate energy for cellular functions.

By Deena Beasley

Federal health officials have approved the first pill to specifically treat depression after childbirth